MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Dicerna Pharmaceuticals Company Profile (NASDAQ:DRNA)

Consensus Ratings for Dicerna Pharmaceuticals (NASDAQ:DRNA) (?)
Ratings Breakdown: 1 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $15.00 (374.68% upside)

Analysts' Ratings History for Dicerna Pharmaceuticals (NASDAQ:DRNA)
Show:
DateFirmActionRatingPrice TargetActions
5/10/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Jefferies GroupReiterated RatingBuy$19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Stifel NicolausLower Price TargetBuy$20.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/14/2016Chardan CapitalReiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Dicerna Pharmaceuticals (NASDAQ:DRNA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/9/2016Q116($0.86)($0.76)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q415($0.84)($0.76)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q315($0.84)($0.82)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.78)($0.86)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q1($0.73)($0.79)$600.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015Q414($0.57)($0.57)$1.45 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014($0.63)($0.63)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014($0.47)($0.64)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q114($0.52)($1.02)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/27/2014($0.62)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Dicerna Pharmaceuticals (NASDAQ:DRNA)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20162($0.92)($0.85)($0.89)
Q3 20162($0.97)($0.94)($0.96)
Q4 20162($1.07)($1.07)($1.07)
(Data provided by Zacks Investment Research)
Dividend History for Dicerna Pharmaceuticals (NASDAQ:DRNA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Dicerna Pharmaceuticals (NASDAQ:DRNA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/12/2016James B WeissmanInsiderBuy5,000$3.29$16,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014James E FlynnInsiderSell321,965$11.36$3,657,522.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/7/2014James E FlynnInsiderSell214,164$9.05$1,938,184.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2014James E FlynnInsiderSell117,778$10.86$1,279,069.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/14/2014James E FlynnMajor ShareholderSell36,115$11.02$397,987.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2014James E FlynnMajor ShareholderSell30,214$12.13$366,495.82View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2014James E FlynnInsiderBuy1,000,000$15.00$15,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2014Stephen J HoffmanDirectorBuy200,000$15.00$3,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Dicerna Pharmaceuticals (NASDAQ:DRNA)
DateHeadline
06/24/16 03:47 PMPost Holdings, Inc. (NYSE:POST) increased 3.76%: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), U.S. Bancorp ... - KC Register
06/23/16 02:37 PMDicerna Pharmaceuticals Inc (NASDAQ:DRNA) Updated Price Targets - FTSE News
06/23/16 07:20 AMDicerna Pharmaceuticals Inc. (DRNA) Hits New 52-week Low During June 21 Session - Equities.com
06/22/16 03:48 PMDicerna Pharmaceuticals Inc. (DRNA) Hits New 52-week Low During June 20 Session - Equities.com
06/19/16 03:28 PMDicerna Pharmaceuticals Inc (NASDAQ:DRNA) Analyst Price Targets For The Coming Week - Fiscal Standard
06/17/16 08:46 AMRecently Issued Stock Ratings For Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) - Fiscal Standard
06/15/16 07:23 AMDICERNA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a -
06/15/16 06:49 AMDicerna Appoints Martin Freed, M.D., to Board of Directors - [at noodls] - 61dbff45-373f-4f48-b1df-a4a0c58e091d.pdf June 15, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, ...
06/02/16 03:15 PMDicerna to Present at the Jefferies 2016 Healthcare Conference - [at noodls] - ecdcad0e-052a-40bf-941f-da1756b1888d.pdf June 2, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, ...
05/26/16 07:12 PMInsiders Are Gradually Buying Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Wall Street Hints and News - Insiders Are Gradually Buying Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) have increased their position in the stock by 8.78% over the past 6 months. Insiders now own 0.30% of total outstanding shares. There are both legal and ...and more »
05/23/16 06:59 PMStock Rating Review for Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Wall Street Hints and News - Stock Rating Review for Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA)Wall Street Hints and NewsCovering equity analysts presently have a consensus stock rating of 1.4 on shares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research.
05/23/16 06:59 PMDicerna Pharmaceuticals (DRNA) Jumps: Stock Rises 8.7% - Nasdaq - Dicerna Pharmaceuticals (DRNA) Jumps: Stock Rises 8.7%NasdaqDicerna Pharmaceuticals, Inc.DRNA was a big mover last session, as its shares rose almost 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. Friday's rally reverses the recent downtrend for ...Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Quarterly EPS From Continuing Operations Stands At $-0.7601Equities FocusBroker Outlook For The Week Ahead Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)Share Trading Newsall 3 news articles »
05/23/16 07:15 AMDicerna Pharmaceuticals (DRNA) Jumps: Stock Rises 8.7% -
05/19/16 12:10 AMShare Recap and Earnings Focus on Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - Wall Street Hints and News - Share Recap and Earnings Focus on Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA)Wall Street Hints and NewsPresently, covering analysts are anticipating Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) to report quarterly EPS of $-0.87. The company's next earnings report is expected to be released on or around 2016-08-04 for the period ending on 2016-06-30.Buy Calls Count For Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) At 0Enterprise Leaderall 935 news articles »
05/19/16 12:10 AMRevenue Update on Dicerna Pharmaceuticals Inc(NASDAQ:DRNA) - Trade Calls - Revenue Update on Dicerna Pharmaceuticals Inc(NASDAQ:DRNA)Trade CallsDicerna Pharmaceuticals Inc(NASDAQ:DRNA) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 9, 2016. Earnings per share were $-0.76. Analysts had estimated an EPS of $-0.86. In a different note, ...
05/16/16 12:23 PMInstitutional Investor's Pro-Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Sentiment In Q4 2015 - Wall Street Hints and News - Institutional Investor's Pro-Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Sentiment In Q4 2015Wall Street Hints and NewsDicerna Pharmaceuticals Inc (NASDAQ:DRNA) institutional sentiment increased to 1.17 in 2015 Q4. Its up 0.27, from 0.9 in 2015Q3. The ratio is positive, as 27 active investment managers opened new or increased equity positions, while 23 sold and trimmed ...Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Is Trading Up - Insider Trading ActivityFinance Dailyall 2 news articles »
05/14/16 06:28 PMDicerna Pharma (DRNA) Doses First Patient in of DCR-PH1 Phase 1 as PH1 Treatment - Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here. Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) announced that the Company has dosed the first patient in its DCR-PH1-101 trial, the first Phase 1 clinical trial of ...
05/14/16 12:31 AMNewLink shares tumble as pancreatic cancer therapy fails - Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) moved down -5.99% to close at $3.45 on 11 May. A number of other brokerages also recently commented on NLNK. The results were followed by negative rating from Cantor Fitzgerald.
05/13/16 07:18 PMDicerna Pharmaceuticals : Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1 (PH1) - Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of RNA interference (RNAi) therapeutics, today announced that the Company has dosed the first patient in its DCR-PH1-101 trial, the first Phase 1 clinical trial of DCR-PH1 in patients with ...
05/13/16 08:58 AMDicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1 (PH1) - [at noodls] - 7229bc1c-e61b-49e4-831b-66dbbfdb5134.pdf May 13, 2016 Milestone for DsiRNA Therapeutic Follows Receipt of Orphan Drug Designation in US and EU CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, ...
05/11/16 07:42 PMDicerna Pharma (DRNA) Plans Presentation of Positive GalNAc-DsiRNA-EX Conjugate Technology Data - StreetInsider.com - Dicerna Pharma (DRNA) Plans Presentation of Positive GalNAc-DsiRNA-EX Conjugate Technology DataStreetInsider.comDicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) will present updated preclinical data demonstrating the potency of its proprietary GalNAc-DsiRNA-EX Conjugate technology in enabling direct delivery of RNAi-based therapy to the liver via subcutaneous (SC) ...and more »
05/11/16 07:42 PMDicerna Pharmaceuticals Inc (DRNA) Hits New 1-Year Low After Analyst Downgrade - Washington News Wire - NewsWay 21Dicerna Pharmaceuticals Inc (DRNA) Hits New 1-Year Low After Analyst DowngradeWashington News WireDicerna Pharmaceuticals logo Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) shares hit a new 52-week low during trading on Wednesday after Stifel Nicolaus lowered their price target on the stock from $20.00 to $16.00, MarketBeat reports. Stifel Nicolaus ...Dicerna Pharmaceuticals Inc (DRNA) Reaches New 52-Week Low on Analyst DowngradeNewsWay 21Dicerna Pharmaceuticals Inc (DRNA) Receives "Buy" Rating from Cowen and CompanyWeb Breaking NewsAre Analysts Bullish Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) After Last Week?Franklin IndependentMarket Digest -Equities Focus -B.O.D.Y Confidentialall 25 news articles »
05/11/16 06:31 AM7:31 am Dicerna Pharmaceuticals will present updated preclinical data on its GalNAc-DsiRNA-EX Conjugate technology in enabling direct delivery of RNAi-based therapy to the liver -
05/11/16 06:30 AMDicerna Reports Potent Preclinical Activity with GalNAc-DsiRNA-EX Conjugates - [Business Wire] - Dicerna Pharmaceuticals, Inc. , a leading developer of investigational RNA interference therapeutics, today will present updated preclinical data demonstrating the potency of its proprietary GalNAc-DsiRNA-EX Conjugate technology in enabling direct delivery of RNAi-based therapy to the liver via subcutaneous injection, with potential utility against multiple therapeutic targets.
05/10/16 07:27 PMAnalysts Offer Insights on Healthcare Companies: Dicerna Pharmaceuticals (NASDAQ: DRNA), SCYNEXIS Inc ... - Markets.co - Analysts Offer Insights on Healthcare Companies: Dicerna Pharmaceuticals (NASDAQ: DRNA), SCYNEXIS Inc ...Markets.coThere's a lot to be optimistic about in the Healthcare sector as 4 experts just weighed in on Dicerna Pharmaceuticals (NASDAQ: DRNA), SCYNEXIS Inc (NASDAQ: SCYX), CytomX Therapeutics Inc. (NASDAQ: CTMX) and Teva Pharmaceutical Industries ...and more »
05/09/16 09:34 PMEdited Transcript of DRNA earnings conference call or presentation 9-May-16 8:30pm GMT -
05/09/16 07:09 PMCheck on Analyst Ratings Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - B.O.D.Y Confidential - Check on Analyst Ratings Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA)B.O.D.Y ConfidentialCovering Wall Street analysts have an average rating of 1.4 on shares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). This Zacks Research number is compiled from analysts that they have taken into consideration. This consensus rating falls on a 1 to 5 ...and more »
05/09/16 04:27 PMDicerna Pharmaceuticals posts 1Q loss -
05/09/16 04:02 PMDICERNA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a -
05/09/16 03:38 PMDicerna Reports First Quarter 2016 Financial and Operational Results - [at noodls] - 8e6467ae-7727-4782-885a-7908b90f4130.pdf May 9, 2016 Management to Host Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading ...
05/09/16 06:07 AMQ1 2016 Dicerna Pharmaceuticals Inc Earnings Release - After Market Close -
05/06/16 07:28 PMMicrocap New Lows: Quantum Corporation (NYSE:QTM), Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), FreightCar ... - KC Register - Microcap New Lows: Quantum Corporation (NYSE:QTM), Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), FreightCar ...KC RegisterOn 3 May, Quantum Corporation (NYSE:QTM) announced that its Xcellis™ high-performance shared workflow storage system won “Best of Show” for postproduction technology in the fifth-annual StudioDaily Prime Awards at the 2016 NAB Show. The award ...
05/05/16 12:33 AMTrader's Recap: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), Wells Fargo (NYSE:WFC), Energy Recovery, Inc ... - KC Register - Trader's Recap: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), Wells Fargo (NYSE:WFC), Energy Recovery, Inc ...KC RegisterDicerna Pharmaceuticals Inc (NASDAQ:DRNA)'s stock had its “neutral” rating reissued by Chardan Capital in a report issued on Thursday, Analyst Ratings.Net reports. On Tuesday Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) share price closed at $4.48.
05/03/16 07:15 PMThis Weeks Broker Price Targets For Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) - Share Trading News - This Weeks Broker Price Targets For Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)Share Trading News04/05/2016 – Chardan Capital began new coverage on Dicerna Pharmaceuticals Inc giving the company a “neutral” rating. They now have a USD 5 price target on the stock. 03/11/2016 – Dicerna Pharmaceuticals Inc had its “buy” rating reiterated by analysts ...Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Basic Consolidated EPS At $-3.0924Equities FocusDicerna to Report First Quarter 2016 Financial Results and Host Conference Call on May 9, 2016Business Wire (press release)all 3 news articles »
05/02/16 03:05 PMDicerna to Report First Quarter 2016 Financial Results and Host Conference Call on May 9, 2016 - [Business Wire] - Dicerna Pharmaceuticals, Inc. , a leading developer of investigational RNA interference therapeutics, today announced that the Company will release its first quarter 2016 financial results after market close on Monday, May 9, 2016.
04/27/16 02:30 AMDicerna Pharmaceuticals Inc (NASDAQ:DRNA) - Broker Update - Risers & Fallers - Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) - Broker UpdateRisers & FallersThe Company develops dacryocystorhinostomy (DCR)-Primary Hyperoxaluria Type 1 (PH1) for the treatment of PH1 by targeting the gene encoding the liver enzyme glycolate oxidase. The Company uses its dicer substrate RNA (DsiRNA)-EX Conjugate ...
04/26/16 07:19 PMDicerna Pharmaceuticals (DRNA) Drops 6.88% on April 25 - Equities.com - Dicerna Pharmaceuticals (DRNA) Drops 6.88% on April 25Equities.comDicerna Pharmaceuticals (DRNA) was one of the Russell 2000's biggest losers for Monday April 25 as the stock slid 6.88% to $4.87, a loss of $-0.36 per share. Starting at an ... Dicerna Pharmaceuticals Inc is a biopharmaceutical company. The Company is ...and more »
04/26/16 07:19 PMShare Performance and Target Price Review Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) - B.O.D.Y Confidential - Share Performance and Target Price Review Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA)B.O.D.Y ConfidentialDuring the most recent trading session, shares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) ended up with a move of -2.46%. Sell-side analysts have given a consensus target price of $16.00 on company shares. Target price projections may differ ...and more »
04/26/16 07:19 PMDicerna Pharmaceuticals Inc (NASDAQ:DRNA) Latest Broker Views - Risers & Fallers - Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Latest Broker ViewsRisers & FallersA number of investment brokers have recently updated their price targets on shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). According to the latest broker reports outstanding on Tuesday 26th of April, 0 analysts have a rating of “strong buy”, ...Morning Watch List: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), Kindred Biosciences, Inc. (NASDAQ:KIN ...Stock Transcriptall 2 news articles »
04/23/16 07:07 PMDicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Has Been Given An ABR Of 1.4 - RealistInvestor.com - Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Has Been Given An ABR Of 1.4RealistInvestor.comAnalysts have a positive outlook on Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) stock. As of 2016-04-23, the stock has been placed an ABR of 1.4. This number comes on a scale of 1 to 5, where one suggests a strong buy call and five indicates Strong ...and more »
04/23/16 02:07 AMDicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Share Rating Recap - The Post - Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Share Rating RecapThe PostShares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly ...and more »
04/22/16 09:02 PMDicerna Pharmaceuticals (DRNA) Jumps 5.44% on April 22 - Equities.com - Dicerna Pharmaceuticals (DRNA) Jumps 5.44% on April 22Equities.comDicerna Pharmaceuticals (DRNA) was among the biggest gainers on the Russell 2000 for Friday April 22 as the stock popped 5.44% to $5.23, representing a gain of $0.27 per share. ... Dicerna Pharmaceuticals Inc is a biopharmaceutical company.and more »
04/22/16 09:02 PMAnalyst Coverage: Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) - Risers & Fallers - Analyst Coverage: Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). The latest broker reports which are currently outstanding on Friday 22nd of April state 0 analysts have a rating of “strong buy ...Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Share Rating RecapThe Postall 2 news articles »
04/05/16 04:59 AMCoverage initiated on Dicerna Pharmaceuticals by Chardan Capital Markets -
03/20/16 08:50 AM8 Biotech Stocks Under $10 Making Big Moves Higher -
03/11/16 10:32 AMEdited Transcript of DRNA earnings conference call or presentation 10-Mar-16 9:30pm GMT -
03/10/16 03:21 PMDicerna Pharmaceuticals posts 4Q loss -
03/10/16 03:00 PMDicerna Announces Fourth Quarter and Full Year 2015 Financial and Operational Results - [Business Wire] - Dicerna Pharmaceuticals, Inc. , a leading developer of investigational RNA interference therapeutics, today announced financial and operational results for the quarter and full year ended December 31, 2015.
03/10/16 06:07 AMQ4 2015 Dicerna Pharmaceuticals Inc Earnings Release - After Market Close -
03/04/16 12:52 PMDicerna to Announce Fourth Quarter and Full Year 2015 Financial Results and Host Conference Call on March 10, 2016 - [Business Wire] - Dicerna Pharmaceuticals, Inc. , a leading developer of investigational RNA interference therapeutics, announced that the Company will release its fourth quarter and full year 2015 financial results after market close on Thursday, March 10, 2016.
About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals logoDicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company uses its RNAi technology platform to build a pipeline in these therapeutic areas. The Company develops dacryocystorhinostomy (DCR)-Primary Hyperoxaluria Type 1 (PH1) for the treatment of PH1 by targeting the gene encoding the liver enzyme glycolate oxidase. The Company uses its dicer substrate RNA (DsiRNA)-EX Conjugate technology to develop a subcutaneously injected treatment for PH1. The Company develops DCR-MYC for the treatment of MYC-related cancers, including hepatocellular carcinoma (HCC) and pancreatic neuroendocrine tumors (PNET).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: DRNA
  • CUSIP:
Key Metrics:
  • Previous Close: $3.16
  • 50 Day Moving Average: $3.56
  • 200 Day Moving Average: $6.19
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $65.49M
  • Current Quarter EPS Consensus Estimate: $-3.43 EPS
Additional Links:
Dicerna Pharmaceuticals (NASDAQ:DRNA) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha